Sidley Discusses Limits to Caremark Claims

Key Takeaways

• Delaware Chancery upheld narrow scope of Caremark claims.
• Board oversight, not perfect outcomes, satisfies fiduciary duty.
• Demand futility denied when majority independent and exculpated.
• Courts require actual knowledge of legal non‑compliance for liability.
• Third‑party fraud does not trigger Caremark liability for directors.

Pulse Analysis

The Delaware Court of Chancery’s Marchner v. B. Riley Financial decision reinforces a long‑standing limitation on the so‑called Caremark doctrine. Originating from the 1996 Caremark International case, the doctrine allows shareholders to sue directors for bad‑faith oversight failures, but the court emphasized that liability only arises when directors *actually* know of illegal conduct and consciously ignore it. In Marchner, the board’s routine audit‑committee processes and the absence of any internal misconduct meant the claim could not be framed as a fiduciary breach, even though the investment later soured due to a third‑party fraud scandal.

The ruling also clarified the application of the Delaware Supreme Court’s Zuckerberg demand‑futility test. Because a majority of directors were independent, received ordinary compensation, and faced no substantive likelihood of liability—thanks in part to a § 102(b)(7) exculpatory clause—the court found demand was not futile. Moreover, the court rejected the notion that ordinary business risks, such as declining projections or debt downgrades, satisfy the “red‑flag” prong of Caremark. Directors must demonstrate concrete knowledge of legal non‑compliance, not merely hindsight awareness of poor investment outcomes.

For boards, the decision sends a clear signal: robust, documented oversight mechanisms are the best defense against derivative suits. Maintaining active audit committees, engaging independent advisors, and promptly investigating any warning signs can satisfy the heightened scrutiny of Caremark claims. Practitioners should also ensure exculpatory provisions are properly drafted to shield directors from duty‑of‑care allegations while recognizing that such clauses do not immunize against bad‑faith oversight claims. As investors increasingly scrutinize ESG and compliance risks, the Marchner precedent will likely curb speculative Caremark litigation and focus disputes on genuine breaches of legal duty.